-
公开(公告)号：US20220144872A1
公开(公告)日：2022-05-12
申请号：US17350267
申请日：2021-06-17
IPC分类号： C07F15/02 , C07C51/41 , A61K33/26 , A61K31/295 , C07C59/265
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
公开(公告)号：US10898459B2
公开(公告)日：2021-01-26
申请号：US15814767
申请日：2017-11-16
发明人： Keith Chan , Winston Town
IPC分类号： A61K31/295 , A61K9/14 , A61K31/555 , A61K33/26
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
-
公开(公告)号：US20180133191A1
公开(公告)日：2018-05-17
申请号：US15814767
申请日：2017-11-16
发明人： Keith Chan , Winston Town
IPC分类号： A61K31/295 , A61K33/26 , A61K9/14 , A61K31/555
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
-
公开(公告)号：US09913821B2
公开(公告)日：2018-03-13
申请号：US15143987
申请日：2016-05-02
IPC分类号： A61K31/295
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
公开(公告)号：US09328133B2
公开(公告)日：2016-05-03
申请号：US14502774
申请日：2014-09-30
IPC分类号： C07C51/41 , C07F15/02 , A61K31/295
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
6.发明公开公开(公告)号：US20240122856A1
公开(公告)日：2024-04-18
申请号：US18397342
申请日：2023-12-27
发明人： Ming-Thau SHEU , Yu-Ying HSU , Yu-De SU , Yu-Hsuan LIU , Pu-Sheng WEI
CPC分类号： A61K9/1682 , A61K9/10 , A61K9/1647 , A61K9/19 , A61K47/10 , A61K47/26 , A61K47/38
摘要： A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected. The polylactic acid microsphere and the polylactic-co-glycolic acid microsphere are respectively the accumulation of the polylactic acid and polylactic-co-glycolic acid, having a smooth surface and a mean number particle size distribution (MN) from 10 μm to 80 μm.
-
公开(公告)号：US20220313612A1
公开(公告)日：2022-10-06
申请号：US17219179
申请日：2021-03-31
发明人： Ming-Thau SHEU , Yu-Ying HSU , Yu-De SU , Yu-Hsuan LIU , Pu-Sheng WEI
摘要： A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected. The polylactic acid microsphere and the polylactic-co-glycolic acid microsphere are respectively the accumulation of the polylactic acid and polylactic-co-glycolic acid, having a smooth surface and a mean number particle size distribution (MN) from 10 μm to 80 μm.
-
公开(公告)号：US20170095441A1
公开(公告)日：2017-04-06
申请号：US15143987
申请日：2016-05-02
IPC分类号： A61K31/295
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
公开(公告)号：US20140018420A1
公开(公告)日：2014-01-16
申请号：US14011357
申请日：2013-08-27
IPC分类号： C07C59/265
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
公开(公告)号：US20130345460A1
公开(公告)日：2013-12-26
申请号：US14011291
申请日：2013-08-27
IPC分类号： C07F15/02
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.017 秒)
